The FDA just changed the rules on peptides effective April 15, 2026. BPC 157, GHK Cu, MOTS C, and TB 500 have been removed from the Category 2 restricted compounding list. Here is what FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea Is BPC157 Legal? WADA, FDA Status, and What You Need to Know BPC 157: What It Is, What We Know, and Why Its Use for Arthritis Remains Unproven San Diego Orthobiologics Medical Group FDA's Overreach on Compounded Peptides